Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;55(1):285-291.
doi: 10.1080/07853890.2022.2160491.

Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis

Affiliations

Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis

Muhammad Muneeb Hassan et al. Ann Med. 2023 Dec.

Abstract

Background: The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pulmonary disease (COPD), with numerous infections in COVID-19 patients.

Objectives: Priority is placed on determining the patient's prognosis based on the presence or absence of TB and COPD. Additionally, a comparison is made between the risk of death and the likelihood of recovery in terms of time in COVID-19 patients who have either COPD or TB.

Methodology: At the DHQ Hospital in Muzaffargarh, Punjab, Pakistan, 498 COVID-19 patients with TB and COPD were studied retrospectively. The duration of study started in February 2022 and concluded in August 2022. The Kaplan-Meier curves described time-to-death and time-to-recovery stratified by TB and COPD status. The Wilcoxon test compared the survival rates of people with TB and COPD in two matched paired groups and their status differences with their standard of living.

Results: The risk of death in COVID-19 patients with TB was 1.476 times higher than in those without (95% CI: 0.949-2.295). The recovery risk in COVID-19 patients with TB was 0.677 times lower than in those without (95% CI: 0.436-1.054). Similarly, patients with TB had a significantly shorter time to death (p=.001) and longer time to recovery (p=.001).

Conclusions: According to the findings, the most significant contributor to an increased risk of morbidity and mortality in TB and COPD patients was the COVID-19.KEY MESSAGESSARS-Cov-19 is a new challenge for the universe in terms of prevention and treatment for people with tuberculosis and chronic obstructive pulmonary disease, among other diseases.Propensity score matching to control for potential biases.Compared to hospitalized patients with and without (TB and COPD) had an equivalently higher mortality rate.

Keywords: COVID-19; Chronic obstructive pulmonary disease; SARS- CoV-2; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflicts of interest.

Figures

Figure 1.
Figure 1.
Survival analysis (a) in fully matched samples with TB, time-to-death and survival evaluated the survival function. (b) Time-to-death and survival evaluated the hazard function in fully matched samples with TB. (c) Time-to-death and survival evaluated the survival function in fully matched samples without TB. (d) Time-to-death and survival evaluated the hazard function in fully matched samples without TB.

References

    1. Center for Systems Science and Engineering at Johns Hopkins University . COVID-19 dashboard; 2022. Available from: https://coronavirus.jhu.edu/map.html
    1. Liu Y, Han X, Cui X, et al. Association between air pollutants and acute exacerbation of chronic obstructive pulmonary disease: a time stratified case-crossover design with a distributed lag nonlinear model. GeoHealth. 2022;6(2):e2021GH000529. - PMC - PubMed
    1. Burić DJ, Erceg M, Antoljak N.. Gender differences in specific trends of COPD mortality in Croatia. Public Health. 2022;202:26–31. - PubMed
    1. World Health Organization (WHO) . Global tuberculosis report 2022. License: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globa...
    1. Gong W, Parkkila S, Wu X, et al. SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies. Int Rev Immunol. 2022:1–22. - PubMed

MeSH terms